Department for Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Dean's Office - Curriculum Development, Hannover Medical School, Hannover, Germany.
Oncology. 2022;100(10):536-541. doi: 10.1159/000525601. Epub 2022 Jun 27.
Overexpression of tumor-associated growth arrest-specific protein 6 (Gas6) is found in many tumor entities. The prognostic value of Gas6 in renal cell carcinoma (RCC), especially in non-clear cell RCC, is still unclear.
The aim of the study was to evaluate the prognostic impact of Gas6 expression in a large cohort of patients with chromophobe RCC (chRCC).
Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for Gas6 expression by immunohistochemistry.
Eighty-one chRCC patients were eligible for analysis; of these, 24 (29.6%) patients were positive for Gas6. No significant associations were found for Gas6 expression and clinical attributes in patients with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Gas6- compared to Gas6+ (89.6% vs. 100.0%; p = 0.288) tumors.
In chRCC, Gas6 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted.
在许多肿瘤实体中发现肿瘤相关生长停滞特异性蛋白 6（Gas6）的过表达。Gas6 在肾细胞癌（RCC）中的预后价值，特别是在非透明细胞 RCC 中，仍然不清楚。
本研究旨在评估 Gas6 表达在大量嗜铬细胞瘤（chRCC）患者中的预后影响。
回顾性评估因 chRCC 而行肾手术的患者。通过免疫组织化学分析肿瘤标本中 Gas6 的表达。
81 例 chRCC 患者符合分析条件；其中，24 例（29.6%）患者 Gas6 阳性。Gas6 表达与 chRCC 患者的临床特征之间没有显著关联。Kaplan-Meier 分析显示，Gas6-与 Gas6+（89.6% vs. 100.0%；p=0.288）肿瘤的 5 年总生存率无差异。
在 chRCC 中，Gas6 表达与生存和其他侵袭性参数无关。由于 chRCC 的发病率较低，需要进一步进行更大队列的研究。
